论文部分内容阅读
为研究１ 种新的过继免疫化疗治疗肝癌的方法，采用肝癌细胞株Ｈ２２ 接种于近交系Ｂａｌｂ／ｃ 小鼠皮下，制成肿瘤模型。使用ＩＬ２ 、肿瘤活化的杀伤细胞（ＡＫ细胞）及环磷酰胺（Ｃｙ） 进行治疗，检测小鼠脾淋巴细胞ＮＫ、ＬＡＫ及ＣＴＬ 活性，用流式细胞仪检测Ｌ３Ｔ４ 亚群及Ｌｙｔ２ 亚群含量。结果表明在过继免疫化疗组小鼠ＬＡＫ 及ＣＴＬ活性明显高于其它治疗组（Ｐ＜ ０．０１），荷瘤小鼠肿瘤结节生长较ＩＬ２ 组及Ｃｙ 组明显缓慢（Ｐ＜ ０．０１），生存期也明显高于其它各治疗组（Ｐ＜０ ．０１）。该研究表明过继免疫化疗有较强的抗肿瘤作用。
In order to study a new method of adoptive immunochemotherapy for liver cancer, hepatoma cell line H22 was inoculated subcutaneously into inbred Balb/c mice to make a tumor model. IL-2, tumor-activated killer cells (AK cells) and cyclophosphamide (Cy) were used to detect the activity of NK, LAK and CTL in spleen lymphocytes of mice, and L3T4 subpopulations and Lyt-2 were detected by flow cytometry. Subgroup content. The results showed that the LAK and CTL activity in the adoptive immunotherapy group was significantly higher than that in other treatment groups (P<0.01). Tumor nodule growth in the tumor-bearing mice was significantly slower than that in the IL-2 group and Cy group (P<0. 01) The survival period was also significantly higher than other treatment groups (P < 0.01). This study shows that adoptive immunotherapy has a strong anti-tumor effect.